CG
EGRX

Cutler Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cutler Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,600
Closed -$40K – 4810
2019
Q4 		$40K Buy
+7,600
New +$453K ﹤0.01% 1785
2018
Q4 		– Sell
-17,500
Closed -$35K – 4733
2018
Q3 		$35K Sell
17,500
-13,600
-44% -$1.03M ﹤0.01% 1852
2018
Q2 		$151K Buy
31,100
+24,800
+394% +$1.56M 0.01% 908
2018
Q1 		$2K Hold
6,300
– – ﹤0.01% 3881
2017
Q4 		$8K Sell
6,300
-1,800
-22% -$100K ﹤0.01% 3329
2017
Q3 		$26K Sell
8,100
-2,100
-21% -$127K ﹤0.01% 2890
2017
Q2 		$63K Sell
10,200
-500
-5% -$40.9K ﹤0.01% 2279
2017
Q1 		$86K Sell
10,700
-11,100
-51% -$825K ﹤0.01% 1880
2016
Q4 		$242K Sell
21,800
-14,900
-41% -$1.08M 0.01% 1165
2016
Q3 		$299K Sell
36,700
-18,900
-34% -$1.05M 0.01% 916
2016
Q2 		$102K Sell
55,600
-70,900
-56% -$2.95M 0.01% 1683
2016
Q1 		$712K Buy
126,500
+115,400
+1,040% +$7.32M 0.05% 377
2015
Q4 		$112K Buy
+11,100
New +$876K 0.01% 1656

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Cutler Group's EGRX Position: Q1 2022 in Review

Cutler Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 803 shares — an estimated $40K sold.

Cutler Group first reported a position in EGRX in Q4 2015 and held it in 14 quarters. The position peaked at $236K in Q4 2015. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Cutler Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 803 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $40K.
  • Cutler Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
  • Cutler Group's Eagle Pharmaceuticals, Inc. position peaked at $236K in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.